公开(公告)号：US20240409653A1

公开(公告)日：2024-12-12

申请号：US18698354

申请日：2022-10-05

Applicant: GENMAB A/S ,  BIONTECH SE ,  MSD INTERNATIONAL BUSINESS GMBH

Inventor： Alexander MUIK ,  Kristina NÜRMBERGER ,  Nora PENCHEVA ,  Maria N. JURE-KUNKEL ,  Ugur SAHIN

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

Abstract: The present disclosure relates to combination therapy using a binding agent that binds to human PD-L1 and to human CD 13 7 in combination with pembrolizumab to reduce or prevent progression of a tumor or treating cancer.

公开(公告)号：US20240335511A1

公开(公告)日：2024-10-10

申请号：US18268124

申请日：2021-12-20

Applicant: BioNTech SE

Inventor： Ugur SAHIN ,  Alexander MUIK ,  Lena Mareen KRANZ ,  Mathias VORMEHR ,  Sina FELLERMEIER-KOPF ,  Jan DIEKMANN ,  David EISEL

IPC: A61K38/20 ,  A61K9/51 ,  A61K38/38 ,  A61K48/00 ,  A61P35/00 ,  C07K14/54 ,  C07K14/55 ,  C07K14/765

CPC classification number: A61K38/2046 ,  A61K9/5146 ,  A61K38/2013 ,  A61K38/38 ,  A61K48/0041 ,  A61P35/00 ,  C07K14/5418 ,  C07K14/55 ,  C07K14/765 ,  C07K2319/31

Abstract: This disclosure relates to the field of therapeutic RNA to treat cancer, in particular advanced solid tumors such as metastatic (Stage IV) or unresectable localized cancer. Disclosed herein are compositions, uses, and methods for treatment of cancers. Administration of therapeutic RNAs to a patient having cancer disclosed herein can reduce tumor size, prolong time to progressive disease, and/or protect against metastasis and/or recurrence of the tumor and ultimately extend survival time.

公开(公告)号：US20230145774A1

公开(公告)日：2023-05-11

申请号：US17907013

申请日：2021-03-30

Applicant: BIONTECH SE ,  TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ

Inventor： Ugur SAHIN ,  Lena Mareen KRANZ ,  Mustafa DIKEN ,  Lina HILSCHER ,  Sebastian KREITER

IPC: A61K39/00 ,  A61K39/39 ,  A61P37/02

CPC classification number: A61K39/0011 ,  A61K39/39 ,  A61P37/02 ,  A61K2039/55561 ,  A61K2039/55538 ,  A61K2039/55527 ,  A61K2039/55522

Abstract: The present disclosure relates to methods and agents for antigen vaccination and inducing effective antigen-specific immune effector cell responses such as T cell responses. Specifically, the present disclosure relates to methods comprising administering to a subject (i) non-immunogenic RNA encoding a peptide or protein comprising an epitope for inducing an immune response against an antigen in the subject, i.e., non-immunogenic RNA encoding vaccine antigen; and (ii) an immunostimulant or RNA encoding an immunostimulant. Administering to the subject non-immunogenic RNA encoding vaccine antigen may provide (following expression of the RNA by appropriate target cells) vaccine antigen for stimulation, priming and/or expansion of immune effector cells and, thus, may induce an immune response against vaccine antigen (and disease-associated antigen) in the subject.

公开(公告)号：US20210317225A1

公开(公告)日：2021-10-14

申请号：US17345628

申请日：2021-06-11

Applicant: GENMAB A/S ,  BioNTech SE

Inventor： Isil ALTINTAS ,  David SATIJN ,  Rik RADEMAKER ,  Paul PARREN ,  Friederike GIESEKE ,  Ugur SAHIN

IPC: C07K16/28 ,  A61K39/395 ,  G01N33/569

Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.

公开(公告)号：US20210163616A1

公开(公告)日：2021-06-03

申请号：US17172694

申请日：2021-02-10

Applicant: GENMAB A/S ,  BIONTECH SE

Inventor： Isil ALTINTAS ,  David SATIJN ,  Rik RADEMAKER ,  Paul PARREN ,  Ugur SAHIN ,  Friederike GIESEKE ,  Alexander MUIK ,  Christian GRUNWITZ

IPC: C07K16/28

Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.

公开(公告)号：US20200247899A1

公开(公告)日：2020-08-06

申请号：US16855703

申请日：2020-04-22

Applicant: GENMAB A/S ,  BIONTECH SE

Inventor： Isil ALTINTAS ,  David SATIJN ,  Rik RADEMAKER ,  Paul PARREN ,  Friederike GIESEKE ,  Ugur SAHIN

IPC: C07K16/28 ,  A61K39/395 ,  G01N33/569

Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.

公开(公告)号：US20250025505A1

公开(公告)日：2025-01-23

申请号：US18717782

申请日：2022-12-08

Applicant: BioNTech SE

Inventor： Ugur SAHIN ,  Petra OEHM ,  Benjamin RENGSTL ,  Katharina REINHARD ,  Liane Monika PREUSSNER ,  Özlem TÜRECI

IPC: A61K35/17 ,  A61K9/127 ,  A61K9/51 ,  A61K31/7105 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28 ,  C12N5/0783

Abstract: The present disclosure relates to chimeric antigen receptor (CAR) expressing immune effector cells showing highly specific and sensitive recognition of CLDN6 expressing cancer cells as well as a high potential for treating cancer in humans.

公开(公告)号：US20240415946A1

公开(公告)日：2024-12-19

申请号：US18699937

申请日：2022-10-10

Applicant: BIONTECH SE ,  TRON-TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBE

Inventor： Ugur SAHIN ,  David WEBER ,  Carina WALTER ,  Diana BAREA ROLDÁN ,  Ruprecht KUNER ,  Melanie HEIN ,  Martin SUCHAN, ,  Vetena KISSLER ,  Lena Mareen KRANZ

IPC: A61K39/00 ,  A61K9/00 ,  A61K9/127 ,  A61P35/00

Abstract: This disclosure relates to the field of RNA to treat lung cancer, in particular non-small-cell lung carcinoma (NSCLC). Lung cancer is the third most frequent malignancy in women and the second most frequent malignancy in men. NSCLC accounts for about 85% of all lung cancers. Disclosed herein are compositions, uses, and methods for treatment of lung cancers. Administration of therapeutic RNAs to a patient having lung cancer disclosed herein can reduce tumor size, prolong time to progressive disease, and/or protect against metastasis and/or recurrence of the tumor and ultimately extend survival time.

公开(公告)号：US20240415828A1

公开(公告)日：2024-12-19

申请号：US18704537

申请日：2022-11-09

Applicant: BIONTECH SE

Inventor： Ugur SAHIN ,  Hariz Iskandar Bin HASSAN ,  Stefan STROBL ,  Roman RÖSEMANN

IPC: A61K31/4745 ,  A61K9/00 ,  A61K31/555 ,  A61K31/7048 ,  A61K39/00 ,  A61P35/00 ,  C07D471/04 ,  C07K16/28

Abstract: The present disclosure relates to the specific TLR7 agonist BNT411, such as compositions and kits comprising BNT411, and the use of BNT411 as immunotherapeutic agent in monotherapy and combination therapy to reduce or prevent progression of a tumor, in particular a solid tumor, or treating cancer, in particular a solid cancer.

公开(公告)号：US20240262924A1

公开(公告)日：2024-08-08

申请号：US18570257

申请日：2022-06-20

Applicant: GENMAB A/S ,  BioNTech SE

Inventor： Ugur SAHIN ,  Alexander MUIK ,  Ulf FORSSMANN ,  Maria N. JURE-KUNKEL ,  Gaurav BAJAJ ,  Craig THALHAUSER ,  Nora PENCHEVA

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

CPC classification number: C07K16/2878 ,  A61P35/00 ,  C07K16/2827 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/31

Abstract: The present invention relates to a method for reducing or preventing progression of a tumor or treating cancer in a subject, comprising administering to the subject a binding agent comprising a first antigen-binding region binding to human CD137, and a second antigen-binding region binding to human PD-L1. The invention further provides a binding agent for use in reducing or preventing progression of a tumor or for use in treatment of cancer.